PDX Pharmaceuticals, Inc
- Biotech or pharma, therapeutic R&D
PDX Pharma’s patented Pdx-NP™ nanoparticle platform enables delivery of a wide range of therapeutics—including siRNA, immunotherapies, and tumor-homing antibodies—to tumor tissues beyond the liver. Its lead therapeutic candidates not only kill cancer cells but also stimulate robust antitumor immune responses. This versatile platform has demonstrated efficacy via both systemic and intratumoral administration across multiple solid tumor models. The technology’s credibility is backed by six issued U.S. patents, numerous high-impact peer-reviewed publications, over $10 million in NIH/NCI grant funding, and $3.5 million in seed investment. PDX Pharma is also a finalist in the BIO International Convention’s Start-Up Stadium, pitching on June 19 at 11:20 AM.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}